- Home
- CRT vs IGC Comparison
CRT vs IGC Comparison
Compare CRT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- IGC
- Stock Information
- Founded
- CRT 1991
- IGC 2005
- Country
- CRT United States
- IGC United States
- Employees
- CRT N/A
- IGC N/A
- Industry
- CRT Oil & Gas Production
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- IGC Health Care
- Exchange
- CRT Nasdaq
- IGC Nasdaq
- Market Cap
- CRT 45.2M
- IGC 39.8M
- IPO Year
- CRT 1992
- IGC N/A
- Fundamental
- Price
- CRT $7.11
- IGC $0.40
- Analyst Decision
- CRT
- IGC Strong Buy
- Analyst Count
- CRT 0
- IGC 2
- Target Price
- CRT N/A
- IGC $4.00
- AVG Volume (30 Days)
- CRT 27.3K
- IGC 739.7K
- Earning Date
- CRT 01-01-0001
- IGC 11-11-2025
- Dividend Yield
- CRT 10.37%
- IGC N/A
- EPS Growth
- CRT N/A
- IGC N/A
- EPS
- CRT 0.92
- IGC N/A
- Revenue
- CRT $6,559,820.00
- IGC $1,327,000.00
- Revenue This Year
- CRT N/A
- IGC $3.54
- Revenue Next Year
- CRT N/A
- IGC $15.12
- P/E Ratio
- CRT $7.78
- IGC N/A
- Revenue Growth
- CRT N/A
- IGC 24.95
- 52 Week Low
- CRT $7.12
- IGC $0.25
- 52 Week High
- CRT $13.31
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CRT 27.77
- IGC 48.66
- Support Level
- CRT $7.38
- IGC $0.39
- Resistance Level
- CRT $7.72
- IGC $0.43
- Average True Range (ATR)
- CRT 0.18
- IGC 0.02
- MACD
- CRT -0.00
- IGC -0.00
- Stochastic Oscillator
- CRT 5.88
- IGC 40.18
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.